Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12144509 | 0.87 | PTGDR2 (0.49) | S1PR4PTGDR2AAK1CYP3A4USP2 | |
| SCHEMBL8236376 | 0.83 | S1PR4 (0.50) | S1PR4PTGDR2 | |
| SCHEMBL18704596 | 0.80 | S1PR4 (0.54) | S1PR4PTGDR2USP2SLC6A4 | |
| SCHEMBL17143366 | 0.80 | AAK1 (0.65) | AAK1CYP3A4GSK3APRKG2MKNK2 | |
| SCHEMBL17143603 | 0.80 | AAK1 (0.65) | AAK1CYP3A4GSK3APRKG2MKNK2 | |
| SCHEMBL3590426 | 0.79 | AAK1 (0.52) | PTGDR2AAK1SLC6A4 | |
| SCHEMBL30006527 | 0.78 | S1PR4 (0.46) | S1PR4PTGDR2USP2ALPLALOX15 | |
| SCHEMBL2273425 | 0.77 | S1PR4 (0.44) | S1PR4PTGDR2SLC6A4KDM1A | |
| SCHEMBL29427047 | 0.77 | S1PR4 (0.44) | S1PR4PTGDR2SLC6A4KDM1A | |
| SCHEMBL2146473 | 0.77 | S1PR4 (0.51) | S1PR4PTGDR2KDM1ANPY1RMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | S1PR4 2355/4885PTGDR2 3811/4885AAK1 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.